Market Overview

UPDATE: Canaccord Genuity Reiterates Buy Rating, Raises PT on TearLab Corporation

Related TEAR
Markets Open Higher; Wal-Mart Lowers Earnings Forecast
Manoj Venkiteshwar Joins TearLab As VP Of Medical Affairs

In a report published Monday, Canaccord Genuity reiterated its Buy rating on TearLab Corporation (NASDAQ: TEAR), and raised its price target from $6.00 to $8.00.

Canaccord Genuity noted, “Given strong underlying business trends, we increase our price target to $8 from $6 as we believe the growth profile of the stock justifies a higher multiple. In our opinion, TEAR should start benefitting from physician referrals (>500 IB), expanding sales force (12 reps and four managers), and robust lead activity from AAO conference.”

TearLab Corporation closed on Friday at $5.31.

Latest Ratings for TEAR

Aug 2014Feltl & Co.DowngradesStrong BuyBuy
May 2014Canaccord GenuityMaintainsBuy
Jul 2013Sidoti & Co.DowngradesBuyNeutral

View More Analyst Ratings for TEAR
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings


Related Articles (TEAR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional